| pubmed-article:17089127 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0334634 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0025241 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0242793 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C1831743 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C1551022 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:17089127 | lifeskim:mentions | umls-concept:C1961136 | lld:lifeskim |
| pubmed-article:17089127 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:17089127 | pubmed:dateCreated | 2007-1-11 | lld:pubmed |
| pubmed-article:17089127 | pubmed:abstractText | The hyper-CVAD + rituximab (R) programme consists of fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone + R alternating with high-dose methotrexate + cytarabine (HD MTX/ARA-C) + R. This regimen, when used as initial therapy for patients under 65 years of age with previously untreated mantle cell lymphoma (MCL), results in remission rates of > 85% with a median event-free survival (EFS) of > 50 months, but with a pattern of continuous relapse out to 60 months. We performed a study of hyper-CVAD + R, followed by consolidative peripheral blood progenitor cells autograft [autologous stem cell transplant (AuSCT)] with high-dose busulfan and melphalan (Bu/Mel) conditioning, in patients with responsive disease. Thirteen patients with a median age of 54 (range = 33-61) were treated. Complete remission (CR) was achieved in 12 patients (92%) after hyper-CVAD + R and 12 completed AuSCT after Bu/Mel conditioning. One patient died during the autograft and another declined AuSCT after achieving a CR with hyper-CVAD + R. With a median follow-up from diagnosis of 36 months (range = 16-53 months), the observed 36 months overall survival and EFS are both 92% for the whole cohort. These data confirm the excellent CR rates achieved by the use of hyper-CVAD + R in patients with MCL and suggest that consolidation with Bu/Mel and AuSCT may improve durable disease control when compared to published outcomes of hyper-CVAD + R alone. | lld:pubmed |
| pubmed-article:17089127 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17089127 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17089127 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17089127 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:17089127 | pubmed:issn | 1432-0584 | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:ThompsonSS | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:SvábZZ | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:RobertsA WAW | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:HoytRR | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:PrinceH MHM | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:GriggA PAP | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:SeymourJ FJF | lld:pubmed |
| pubmed-article:17089127 | pubmed:author | pubmed-author:RitchieD SDS | lld:pubmed |
| pubmed-article:17089127 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17089127 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:17089127 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17089127 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17089127 | pubmed:pagination | 101-5 | lld:pubmed |
| pubmed-article:17089127 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:meshHeading | pubmed-meshheading:17089127... | lld:pubmed |
| pubmed-article:17089127 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17089127 | pubmed:articleTitle | The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. | lld:pubmed |
| pubmed-article:17089127 | pubmed:affiliation | Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. david.ritchie@petermac.org | lld:pubmed |
| pubmed-article:17089127 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17089127 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17089127 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17089127 | lld:pubmed |
